- 专利标题： Spiro-lactam NMDA modulators and methods of using same
-
申请号： US17831547申请日： 2022-06-03
-
公开(公告)号： US12084444B2公开(公告)日： 2024-09-10
- 发明人: M. Amin Khan
- 申请人： Tenacia Biotechnology (Hong Kong) Co., Limited
- 申请人地址： HK Sheung Wan
- 专利权人： Tenacia Biotechnology (Hong Kong) Co., Limited
- 当前专利权人： Tenacia Biotechnology (Hong Kong) Co., Limited
- 当前专利权人地址： CN Hong Kong
- 代理机构： Jun He Law Offices P.C.
- 代理商 James J. Zhu
- 分案原申请号： US16322604
- 主分类号： C07D471/10
- IPC分类号： C07D471/10 ; A61K9/00 ; A61P25/02 ; A61P25/06 ; A61P25/18 ; A61P25/22 ; A61P25/24 ; A61P25/28 ; C07D487/10
摘要：
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
公开/授权文献
- US20230128006A1 SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME 公开/授权日：2023-04-27
信息查询
